Endocrine Conditions and COVID-19

Shekhar, Skand; Wurth, Rachel; Kamilaris, Crystal; Eisenhofer, Graeme; Barrera, Francisco J.; Hajdenberg, Michelle; Tonleu, Joselyne; Hall, Janet E.; Schiffrin, Ernesto L.; Porter, Forbes D.; Stratakis, Constantine A.; Hannah‐Shmouni, Fady

doi:10.1055/a-1172-1352

Cited by 40 publications

(46 citation statements)

References 127 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This risk may be explained by a dysregulated immune response, a higher comorbidity burden, and alterations of ACE2 cellular expression [ 6 , 10-12 ]. The latter has been the subject of intense scrutiny, given the lack of evidence against the use of renin-angiotensin system blocking agents and their known benefits in diabetes and hypertension [ 12-14 ], as well as other cardiovascular conditions that have been shown to enhance ACE2 expression [ 15 ].…”

mentioning

confidence: 99%

Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients

Barrera

Shekhar

Wurth

et al. 2020

Journal of the Endocrine Society

Self Cite

View full text Add to dashboard Cite

Covid-19 has impacted millions of people and may disproportionately affect those with hypertension and diabetes. Due to inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched, databases from December 1, 2019 to April 6, 2020 and selected observational peer-reviewed studies in English language of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence using the. We included 65 (15,794 participants) observational studies at moderate-to-high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% CI 10-15%, n=12870, I2: 89%), and 17% (95% CI 13-22%, n=12709, I2: 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI 16-20%, n=1099, I2: 0%) and 32% (95% CI 16-54%, n=1078, I2: 63%), respectively. Unadjusted relative risk for ICU admission and mortality were 1.96 (95% CI 1.19-3.22, n=8,890, I2: 80%, p=.008) and 2.78 (95% CI 1.39-5.58, n=2058, I2: 75%, p=.0004) for diabetics; and 2.95 (95% CI 2.18-3.99, n=1737, I2: 0%, p<.001) and 2.39 (95% CI 1.54-3.73, n=3107, I2: 66%, p<.001) for hypertensives. Neither diabetes (1.50, 95% CI 0.90-2.50, n=1991, I2: 74%, p=.119) nor hypertension (1.48, 95% CI 0.99-2.23, n=2023, I2: 69%, p=.058) was associated with severe Covid-19. In conclusion, the risk of ICU admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared to those without these comorbidities.

show abstract

mentioning

confidence: 99%

Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients

Barrera

Shekhar

Wurth

et al. 2020

Journal of the Endocrine Society

Self Cite

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic requires a joint effort from health care professionals of all areas of knowledge, including endocrinologists, to help fight the progress and consequences of the infection within their areas of expertise (4)(5)(6). Increasing evidence suggests that patients with prior endocrine diseases are at increased risk of developing severe COVID-19 (7)(8)(9), especially individuals with type 2 diabetes mellitus (10,11) or obesity (12), while data on thyroid involvement in SARS-CoV-2 infection are still scarce (13)(14)(15)(16). A few studies that have addressed this area of concern have found associations of COVID-19 infection with abnormalities of the pituitary-thyroid axis (17), subacute thyroiditis (18)(19)(20)(21), Hashimoto's thyroiditis (22), and thyrotoxicosis (23).…”

Section: Introductionmentioning

confidence: 99%

Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)

Martins¹,

Villagelin²,

Carvalho³

et al. 2021

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

“…This is particularly significant as two in three adults in North America are overweight or have obesity [ 14 , 15 , 16 ], thus, a sustained period of weight gain during the pandemic could further aggravate metabolic syndrome [ 6 ]. This has implications for related health conditions like obesity [ 6 , 17 ] and its comorbid diseases, including diabetes [ 18 ], hypertension [ 18 ], and cardiovascular disease [ 19 ] that are significant risk factors for COVID-19 severity [ 20 ]. Indeed, half of patients hospitalized for COVID-19 have obesity [ 21 ], and patients with obesity are also more likely to require a ventilator [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Piece of Cake: Coping with COVID-19

Chee

Anisman

et al. 2020

Nutrients

View full text Add to dashboard Cite

To limit the spread of coronavirus disease 2019 (COVID-19), many individuals were instructed to stay at home, and teleworking became commonplace. Meanwhile, many others were laid off or worked reduced hours, and some front line workers were required to work longer hours. Concurrently, a surge in reports of “pandemic baking” suggested a cascade effect on eating behaviors, which may be an inadvertent strategy to cope with stress. We conducted an online survey of people living in Canada or the United States (N = 680) to assess how employment change may have been experienced as stressful and linked to a shift in food choices. Regression models suggested that reduced hours and being laid off were associated with greater stress appraisals, avoidant- and emotion-focused coping responses, and negative affect. In turn, negative affect was associated with eating to cope and unhealthy snack choices, like salty or sweet treats. Our study emphasizes that under stressful conditions, such as those experienced during the COVID-19 pandemic, some coping strategies may contribute to the greater vulnerability to downstream effects, particularly those relating to eating choices and nutritional balances.

show abstract

Endocrine Conditions and COVID-19

Cited by 40 publications

References 127 publications

Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients

Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients

Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)

Piece of Cake: Coping with COVID-19

Contact Info

Product

Resources

About